ClinicalTrials.gg
CompletedNCT07942649Updated Nov 17, 2026

Circadian Variation in Esophagogastric Variceal Bleeding in Cirrhosis

An observational study in Hepatic Cirrhosis With Variceal Bleeding and Cirrhotic Variceal Bleeding, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
614
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 215 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Enrollment
33rd of 87
614 · median 447
Started
2025
with 19 others
Observational
87 of 215
25 open now
Registered
215th of 215
by date
Lead sponsor
8 of 215
Third Affiliated Hospital, Sun Yat-Sen University

Among the 215 studies in Liver Cirrhosis with a site in China, this one is the 33rd largest by enrollment of the 87 observational ones that give a count, is one of 20 that started in 2025, is one of 87 observational ones, and was the 215th registered.

Liver Cirrhosis

1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 215 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 207 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 65 (31%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 215 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center bidirectional cohort study. The aim is to investigate the potential circadian rhythm of the bleeding pattern of gastric esophageal varices rupture in liver cirrhosis, as well as other related mechanisms and external influencing factors related to the timing. This will help to better prevent the occurrence or aggravation of the disease and provide more effective timing-based treatment and prevention strategies for patients.

Read the detailed description

1.1 Research Background and Objectives: All systems and organs exhibit pathological physiological changes related to circadian rhythms, and thus circadian rhythms are closely associated with the occurrence and development of many diseases. The study of the circadian rhythm of gastric esophageal variceal bleeding in liver cirrhosis involves the first study in 1993 that included 744 cases of bleeding events, which found that the onset time of variceal bleeding (608 cases) in alcoholic liver cirrhosis (279 cases) and non-alcoholic liver cirrhosis (329 cases) showed significant circadian rhythm (P\<0.05), with two peaks occurring at 08:00 and 20:00 respectively. A study in 1996 that included 212 cases of bleeding events also confirmed the circadian rhythm of the bleeding time in patients with liver cirrhosis.

Exploring the potential circadian rhythm of the circadian rhythm of gastric esophageal variceal bleeding in liver cirrhosis, other related mechanisms, and external influencing factors related to the timing, is helpful for better prevention of the occurrence or aggravation of the disease and providing more effective treatment and prevention strategies based on timing for patients.

1.2 Design Type: Prospective, multicenter cross-sectional study 1.3 Study Subjects Inclusion criteria

  1. Over 18 years old
  2. Clinically diagnosed as liver cirrhosis
  3. Obvious signs of acute upper gastrointestinal bleeding, acute upper gastrointestinal bleeding manifested by hematemesis
  4. Informed consent Exclusion criteria

(1) Non-variceal bleeding found by gastroscopy (2) Severe extraliver diseases, heart, lung, kidney, brain dysfunction, excluding liver cirrhosis-induced hepatic encephalopathy, liver-kidney syndrome, liver-pulmonary syndrome (3) Complicated with malignant tumors other than primary liver cancer 1.4 Sample size This study is a cross-sectional study, investigating the time rhythm of variceal bleeding. According to the 2009 study on the time rhythm of variceal bleeding [3], it is divided into 12 time periods. The bleeding rate in the high-incidence period is 20.83%, the expected effect size is 12.5%, the confidence level 1-α = 0.95, and the statistical power 1-β = 0.8. The sample size N = 201 was calculated using PASS 16.0 software. An additional 15% sample size was added using the cosine model, considering a 10% non-response rate, then the required sample size N = 257 cases. The number of cases in this center / total cases = 1/2.

1.5 Observation indicators Demographic information: Name, gender, age, patient ID General condition: Weight, height Medical history: Cause of liver cirrhosis, bleeding method, bleeding date, bleeding time, admission date, admission time, gastroscopy date, gastroscopy time, whether combined with primary liver cancer, whether having chronic diseases, whether using NSBB and anticoagulant platelet inhibitors, whether combined with ascites or hepatic encephalopathy Laboratory tests: Blood routine, blood biochemistry, coagulation; Imaging data: Results of liver and spleen color Doppler ultrasound, spleen length diameter, liver elasticity 1.6 Statistical analysis methods The Cosinor rhythm model was used to perform sinusoidal fitting of the bleeding time, and the changes in 24-hour bleeding rhythm were fitted; qualitative and quantitative differences between subgroups were tested using chi-square test or Fisher's exact test for categorical variables, and Student's t-test or Mann-Whitney U test for continuous variables. Paired t-test or analysis of variance was used to compare the differences in MELD score and Child-Pugh score between time points. Multivariate logistic regression analysis was used to estimate odds ratios (ORs) and their 95% confidence intervals. All statistical tests were two-sided tests. p \< 0.05 was considered statistically significant.

03

Conditions studied

  • Hepatic Cirrhosis With Variceal Bleeding
  • Cirrhotic Variceal Bleeding

Browse trials for

Keywords

  • liver cirrhosis
  • variceal bleeding
  • Cirrhotic Variceal Bleeding
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 18 years or older with clinically diagnosed liver cirrhosis presenting with variceal bleeding manifested as hematemesis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Clinically diagnosed with liver cirrhosis
  • Evident signs of acute upper gastrointestinal bleeding, specifically acute upper gastrointestinal bleeding presenting as hematemesis

Exclusion criteria

Exclusion Criteria:

  • Non-variceal bleeding detected by gastroscopy
  • Severe extrahepatic diseases with cardiac, pulmonary, renal or cerebral insufficiency, excluding hepatic encephalopathy, hepatorenal syndrome and hepatopulmonary syndrome caused by liver cirrhosis
  • Comorbidity with malignant tumors other than primary liver cancer
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
614 participants (actual)
Target follow-up
1 Week
Patient registry
Yes

Groups and cohorts

  • Population with Cirrhosis-related Variceal Bleeding

    Inclusion Criteria 1. Aged 18 years or above 2. Clinically diagnosed with liver cirrhosis 3. Presenting with overt acute upper gastrointestinal bleeding, specifically hematemesis 4. Informed consent obtained Exclusion Criteria (1) Non-variceal bleeding identified on gastroscopy (2) Severe extrahepatic diseases, including cardiopulmonary, renal, or cerebral insufficiency, excluding hepatic encephalopathy, hepatorenal syndrome, and hepatopulmonary syndrome secondary to liver cirrhosis (3) Concurrent malignancy other than primary liver cancer (4) Pregnant or breastfeeding women

06

What researchers measure

Primary outcomes

  1. variceal bleeding

    Acute Variceal Upper Gastrointestinal Bleeding in Liver Cirrhosis Presenting as Hematemesis;After admission, the time of first onset of this bleeding episode was recorded following confirmation via gastroscopic exploration.

    Time frame: Baseline

07

Study locations

1 site
  • The Third Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Oct 2026, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Jul 1, 2025
Primary completionActual
Oct 1, 2026
CompletionActual
Nov 1, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942649
Responsible party
Yifei Huang (resident doctor, Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Nov 17, 2026
Start date
Jul 1, 2025
Primary completion
Oct 1, 2026
Completion
Nov 1, 2026
Last update
Nov 17, 2026

Study contacts

Bin Wu
study chair · Third Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion